Journal of the Society for Cardiovascular Angiography & Interventions最新文献

{"title":"Safety and Efficacy of Percutaneous Ventricular Assist Device vs Intra-Aortic Balloon Pump in Elective High-Risk Percutaneous Coronary Intervention Procedures","authors":"Tayyab Shah MD ,&nbsp;Chantal Holy MSc, PhD ,&nbsp;Ali Almedhychy MD ,&nbsp;Jeffrey W. Moses MD ,&nbsp;Helen Parise ScD ,&nbsp;Alejandro Lemor MD ,&nbsp;William W. O’Neill MD ,&nbsp;Alexandra J. Lansky MD","doi":"10.1016/j.jscai.2025.103997","DOIUrl":"10.1016/j.jscai.2025.103997","url":null,"abstract":"<div><h3>Background</h3><div>This study compares outcomes between percutaneous ventricular assist device (PVAD)-supported and intra-aortic balloon pump (IABP)-supported high-risk percutaneous coronary intervention (HRPCI) in a large-scale, contemporary hospital administrative dataset.</div></div><div><h3>Methods</h3><div>Patients undergoing HRPCI supported by PVAD or IABP between January 1, 2018, and April 30, 2024, were identified in the Premier Healthcare Database. Patients were excluded if they had cardiogenic shock and/or STEMI on admission, received mechanical circulatory support and PCI on different days, required emergent procedures, had multiple mechanical circulatory support devices used, or received coronary artery bypass grafting surgery within the same admission. Variable rate propensity score matching was conducted with 87 preprocedural variables including patient demographic characteristics, comorbidities, prior procedures, prior complications, and provider/hospital factors. The primary end point was the 90-day mortality, and secondary end points included major adverse cardiac and cerebrovascular events (defined as death, myocardial infarction, or stroke), new cardiogenic shock, 30-day acute kidney injury, in-hospital blood transfusions, length of stay, and discharge disposition.</div></div><div><h3>Results</h3><div>A total of 2416 patients who underwent PVAD-assisted HRPCI and 847 patients who underwent IABP-assisted HRPCI (mean age, 72 ± 10.4 years; 66% women; 19% non-White) were matched with good balance among all matched variables. Compared with those who received IABP support, those who received PVAD support had lower 90-day mortality (7.9% vs 11.8%; <em>P</em> = .01), lower 90-day major adverse cardiac and cerebrovascular events (10.3% vs 14.9%; <em>P</em> &lt; .001), less postprocedural cardiogenic shock (9.5% vs 23.5%; <em>P</em> &lt; .001), and less acute kidney injury (9.9% vs 15.6%; <em>P</em> &lt; .001). PVAD-supported patients had shorter mean lengths of stay (4.3 vs 5.7 days; <em>P</em> &lt; .001) and were more likely to be discharged to home. There were no significant differences in rates of blood transfusions (11.3% vs 10.3%; <em>P</em> = .43) or vascular complications between groups.</div></div><div><h3>Conclusions</h3><div>This retrospective observational study suggests that PVAD-supported HRPCI in nonshock patients may be associated with improved clinical outcomes compared with IABP-supported HRPCI; however, future randomized trials are required to confirm this finding.</div></div>","PeriodicalId":73990,"journal":{"name":"Journal of the Society for Cardiovascular Angiography & Interventions","volume":"4 12","pages":"Article 103997"},"PeriodicalIF":0.0,"publicationDate":"2025-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145754171","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Respiratory Support and Mortality Risk Across the Spectrum of Cardiogenic Shock Severity","authors":"Talal El Zarif MD ,&nbsp;Cesar Caraballo MD ,&nbsp;Angela M. Victoria-Castro MD ,&nbsp;Israel Safiriyu MD ,&nbsp;Maria Gabriela Gastanadui MD ,&nbsp;David M. Dudzinski MD ,&nbsp;Balimkiz Senman MD ,&nbsp;Carlos Alviar MD ,&nbsp;Guido Tavazzi MD ,&nbsp;Andrea Elliott MD ,&nbsp;Aniket S. Rali MD ,&nbsp;Mark Jacobs MD ,&nbsp;Jason N. Katz MD, MHS ,&nbsp;Ann Gage MD ,&nbsp;P. Elliott Miller MD, MHS","doi":"10.1016/j.jscai.2025.104043","DOIUrl":"10.1016/j.jscai.2025.104043","url":null,"abstract":"<div><h3>Background</h3><div>The Society for Cardiovascular Angiography &amp; Intervention (SCAI) SHOCK stages classification schema risk-stratifies patients with cardiogenic shock (CS). The updated 2022 SCAI SHOCK stages removed the use of respiratory support, either noninvasive (NIV) or invasive mechanical ventilation (IMV), as a criterion. We sought to investigate the impact of receiving respiratory support on in-hospital mortality for patients with CS stratified by SCAI SHOCK stages.</div></div><div><h3>Methods</h3><div>Utilizing a nationally representative database, adults aged ≥18 years admitted from 2015 to 2023 with a diagnosis of CS were used to assess for the association between respiratory support, either NIV or IMV, on the first day of admission, with in-hospital mortality stratified by SCAI SHOCK stages B through E. We utilized inverse probability treatment weighting, adjusting for demographic characteristics, comorbidities, hospital characteristics, and vasoactive/mechanical circulatory support.</div></div><div><h3>Results</h3><div>We identified 317,325 patients with CS, including 2.4%, 39.0%, 34.2%, and 24.5% with SCAI stages B through E, respectively. Respiratory support was utilized in 38.0% (n = 120,594) of patients, with 5.4% receiving NIV, 33.8% receiving IMV, and 1.1% receiving both on the first day of admission. After inverse probability treatment weighting, respiratory support use remained associated with an increased mortality overall (weighted mean mortality increase of 18.3%; 95% CI, 17.9%-18.7%), when stratified by each SCAI SHOCK stage and in several key sensitivity analyses.</div></div><div><h3>Conclusions</h3><div>Compared with patients not receiving respiratory support, the use of respiratory support was associated with an increased mortality for each SCAI stage of CS and could be a simple, easily identifiable CS risk modifier.</div></div>","PeriodicalId":73990,"journal":{"name":"Journal of the Society for Cardiovascular Angiography & Interventions","volume":"4 12","pages":"Article 104043"},"PeriodicalIF":0.0,"publicationDate":"2025-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145754174","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Comparative Effectiveness of Balloon Aortic Valvuloplasty via Transradial and Transfemoral Access","authors":"Jonathan X. Fang MBBS ,&nbsp;Pedro A. Villablanca MD ,&nbsp;Tiberio M. Frisoli MD ,&nbsp;Pedro Engel Gonzalez MD ,&nbsp;James C. Lee MD ,&nbsp;Georgi K. Fram MD ,&nbsp;Leo Kar Lok Lai MBChB ,&nbsp;Gennaro Giustino MD ,&nbsp;Hussayn Alrayes DO ,&nbsp;Louie B. Kamel-Abusalha BS ,&nbsp;Rama Ellauzi MD ,&nbsp;Samuel Gregerson MD ,&nbsp;Michael Chiang MBBS ,&nbsp;Kent Chak-yu So MBChB ,&nbsp;Dee Dee Wang MD ,&nbsp;William W. O’Neill MD ,&nbsp;Brian P. O’Neill MD","doi":"10.1016/j.jscai.2025.104015","DOIUrl":"10.1016/j.jscai.2025.104015","url":null,"abstract":"<div><h3>Background</h3><div>Balloon aortic valvuloplasty (BAV) is commonly performed as a bridge to therapy, for stratification, or as a palliative procedure in cases of severe aortic stenosis. The complication rate of transfemoral access BAV (transfemoral valvuloplasty [TFV]) is comparable to that of transcatheter aortic valve replacement. Transradial access BAV (transradial valvuloplasty [TRV]) is technically feasible; however, comparative data for TFV are lacking. We aim to compare TFV and TRV in terms of technical and hemodynamic success, periprocedural safety, and short-term clinical outcomes.</div></div><div><h3>Methods</h3><div>Consecutive patients undergoing BAV at a tertiary center from 2021 to 2024 were assessed. TRV was performed with ultrasound guidance and an 8F short sheath equipped with compatible balloons. Hemodynamic success was defined as a reduction in gradient of 30% or more. The primary outcome was the periprocedural composite of a Valve Academic Research Consortium (VARC) 3 major vascular complication, grade 3 to 4 bleeding, and balloon entrapment, and nonaccess-related events, including complete heart block, periprocedural stroke, hypotension, severe aortic insufficiency, and periprocedural death. The secondary outcome was the 30-day composite of all-cause mortality, cardiac-related hospitalization, and discharge failure. Inverse probability of treatment weighting, followed by multivariate regression, was employed to address confounders.</div></div><div><h3>Results</h3><div>105 TRV and 148 TFV were included. Technical success rate was 96.2% for TRV and 98.7% for TFV (<em>P</em> = .21). The primary outcome event rate was significantly lower in the TRV compared to the TFV group: 2.53% vs 17.47%; adjusted odds ratio, 0.13; 95% CI, 0.04-0.49; <em>P</em> = .003. Technical and hemodynamic success and secondary outcomes were comparable between TRV and TFV.</div></div><div><h3>Conclusions</h3><div>In comparison to TFV, TRV is associated with lower rates of periprocedural safety events while maintaining similar short-term clinical outcomes and hemodynamic performance.</div></div>","PeriodicalId":73990,"journal":{"name":"Journal of the Society for Cardiovascular Angiography & Interventions","volume":"4 12","pages":"Article 104015"},"PeriodicalIF":0.0,"publicationDate":"2025-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145754216","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Impact of Left Ventricular End-Diastolic Pressure on Percutaneous Coronary Intervention Outcomes","authors":"Matthew Siano MD ,&nbsp;Yash Jobanputra MD ,&nbsp;Angelo Oliva MD ,&nbsp;Samantha Sartori PhD ,&nbsp;Kenneth Smith MPH ,&nbsp;Harleen Kaur BA ,&nbsp;Joseph Sweeny MD ,&nbsp;George D. Dangas MD, PhD ,&nbsp;Roxana Mehran MD ,&nbsp;Annapoorna S. Kini MD ,&nbsp;Samin K. Sharma MD","doi":"10.1016/j.jscai.2025.104017","DOIUrl":"10.1016/j.jscai.2025.104017","url":null,"abstract":"<div><h3>Background</h3><div>Left ventricular end-diastolic pressure (LVEDP) is associated with adverse outcomes following percutaneous coronary intervention (PCI) for acute coronary syndrome (ACS). We evaluated the impact of LVEDP on outcomes in patients with chronic coronary syndrome or ACS undergoing PCI.</div></div><div><h3>Methods</h3><div>Consecutive patients undergoing PCI between 2014 and 2021 were included. Patients with LVEDP ≤14 mm Hg were compared to those with LVEDP 15 to 20 mm Hg and LVEDP &gt;20 mm Hg. The primary outcome was all-cause mortality at 1 year. A supplemental analysis was conducted in patients with LVEDP &gt;20 mm Hg according to left ventricular ejection fraction.</div></div><div><h3>Results</h3><div>There were significant differences in baseline characteristics between patients with LVEDP ≤14 mm Hg (n = 10,547), LVEDP 15 to 20 mm Hg (n = 5011), and LVEDP &gt;20 mm Hg (n = 1621). Patients with LVEDP &gt;20 mm Hg had the highest prevalence of comorbidities and complexity of coronary artery disease. Compared to patients with LVEDP ≤14 mm Hg, increased all-cause mortality was observed in patients with LVEDP 15 to 20 mm Hg (3.0% vs 1.6%; adjusted hazard ratio [aHR], 1.47; 95% CI, 1.15-1.87; <em>P</em> = .002) and LVEDP &gt;20 mm Hg (7.6% vs 1.6%, aHR, 3.00; 95% CI, 2.31-3.90; <em>P</em> &lt; .001) at 1 year. In patients with LVEDP &gt;20 mm Hg, a left ventricular ejection fraction &lt;40% was associated with increased 1-year all-cause mortality (11.4% vs 2.8%; aHR, 2.71; 95% CI, 1.36-5.37; <em>P</em> = .004).</div></div><div><h3>Conclusions</h3><div>In a population of patients with chronic coronary syndrome and ACS undergoing PCI, elevated LVEDP was associated with increased mortality at 1 year. Systolic dysfunction was associated with higher mortality in patients with LVEDP &gt;20 mm Hg.</div></div>","PeriodicalId":73990,"journal":{"name":"Journal of the Society for Cardiovascular Angiography & Interventions","volume":"4 12","pages":"Article 104017"},"PeriodicalIF":0.0,"publicationDate":"2025-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145754176","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Outcomes After Transcatheter Mitral Valve Replacement in Valve in Valve, Valve in Ring, and Mitral Annular Calcification","authors":"Chikashi Nakai MD ,&nbsp;Augustin DeLago MD ,&nbsp;Sanjay Samy MD","doi":"10.1016/j.jscai.2025.104003","DOIUrl":"10.1016/j.jscai.2025.104003","url":null,"abstract":"<div><h3>Background</h3><div>There are few reports about midterm to long-term outcomes of transcatheter mitral valve replacement (TMVR) in valve in valve (ViV), valve in ring (ViR), and valve in mitral annular calcification (ViM). The aim of this study was to assess postoperative outcomes in patients who underwent TMVR for calcification or failing valves.</div></div><div><h3>Methods</h3><div>Between March 2016 and July 2024, 82 patients underwent TMVR with SAPIEN 3 (Edwards Lifescience) balloon-expandable valve, with 72 transseptal and 10 transapical access. Of 82 patients, 47 had TMVR with ViV/ViR and 35 with ViM. Postprocedural outcomes and midterm survivals were evaluated comparing ViV/ViR group with ViM group.</div></div><div><h3>Results</h3><div>The ViM required more ventricular septal ablation before TMVR for left ventricular outflow tract obstruction (31.4% [11/35] vs 4.3% [2/47]; <em>P</em> &lt; .01). Early hospital mortality was significantly higher in the ViM group (34.5% [12/35] vs 2.1% [1/47]; <em>P</em> &lt; .01). The incidence of postprocedural stroke, left ventricular outflow tract obstruction, permanent pacemaker, and reintervention for mitral valve was similar between the 2 groups. The mean follow-up term was 17.6 ± 22.5 months. The cumulative 5-year survivals in ViV/ViR and ViM were 57.4% and 24.3%, respectively. A significant difference was noted in the midterm outcome between the 2 groups (<em>P</em> &lt; .01). On multivariable Cox proportional hazards analysis, only conducting ViM procedure was associated with an increased midterm mortality (hazard ratio, 2.58; 95% CI, 1.33-4.99; <em>P</em> &lt; .01).</div></div><div><h3>Conclusions</h3><div>Short-term and midterm outcomes of TMVR in ViV and ViR were better than those of ViM in this patient cohort.</div></div>","PeriodicalId":73990,"journal":{"name":"Journal of the Society for Cardiovascular Angiography & Interventions","volume":"4 12","pages":"Article 104003"},"PeriodicalIF":0.0,"publicationDate":"2025-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145754215","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Pitfalls in Comparing Mechanical Circulatory Support Devices Using Administrative Datasets: Epidemiology of the Diseased Population","authors":"Tayyab Shah MD ,&nbsp;Chantal Holy MSc, PhD ,&nbsp;Ali Almedhychy MD ,&nbsp;Jeffrey W. Moses MD ,&nbsp;Helen Parise ScD ,&nbsp;Alejandro Lemor MD ,&nbsp;William W. O’Neill MD ,&nbsp;Alexandra J. Lansky MD","doi":"10.1016/j.jscai.2025.103998","DOIUrl":"10.1016/j.jscai.2025.103998","url":null,"abstract":"","PeriodicalId":73990,"journal":{"name":"Journal of the Society for Cardiovascular Angiography & Interventions","volume":"4 12","pages":"Article 103998"},"PeriodicalIF":0.0,"publicationDate":"2025-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145754172","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"SCAI Position Statement on Intracardiac Echocardiography to Guide Structural Heart Disease Interventions","authors":"Mackram F. Eleid MD, FSCAI ,&nbsp;Christine J. Chung MD ,&nbsp;Matthew J. Daniels MD, PhD, FSCAI ,&nbsp;V. Vivian Dimas MD, FSCAI ,&nbsp;Andrew M. Goldsweig MD, MSc, FSCAI ,&nbsp;Harsh Golwala MD, FSCAI ,&nbsp;Eric M. Horlick MDCM, FRCPC, MSCAI ,&nbsp;Matthew J. Price MD, FSCAI ,&nbsp;Carlos E. Sanchez MD, FSCAI ,&nbsp;John T. Saxon MD, FSCAI ,&nbsp;Markus D. Scherer MD, FSCAI ,&nbsp;Gilbert H.L. Tang MD, MBA, FSCAI ,&nbsp;Dee Dee Wang MD, FSCAI ,&nbsp;Omar K. Khalique MD, FSCAI","doi":"10.1016/j.jscai.2025.103946","DOIUrl":"10.1016/j.jscai.2025.103946","url":null,"abstract":"<div><div>As structural heart disease interventions rapidly evolve, demand for minimally invasive intraprocedural imaging techniques has increased. Intracardiac echocardiography (ICE) has emerged as a valuable imaging modality, offering real-time, high-resolution visualization of cardiac structures without the need for general anesthesia. This position statement from the Society for Cardiovascular Angiography &amp; Interventions outlines the clinical applications, advantages, limitations, and implementation strategies for ICE in guiding transcatheter structural heart disease procedures. The document details standardized ICE imaging protocols and views for interventions involving the mitral, tricuspid, and pulmonary valves, as well as left atrial appendage occlusion atrial septal defect, and patent foramen ovale closure. It emphasizes the importance of operator training, physician workflows, and institutional readiness for successful ICE integration. The statement also advocates for updated reimbursement models that reflect the complexity and value of ICE-guided procedures and calls for further research comparing ICE and transesophageal echocardiography outcomes.</div></div>","PeriodicalId":73990,"journal":{"name":"Journal of the Society for Cardiovascular Angiography & Interventions","volume":"4 12","pages":"Article 103946"},"PeriodicalIF":0.0,"publicationDate":"2025-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145754098","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Protamine Utilization and Clinical Outcomes for Coronary Artery Perforation in Chronic Total Occlusion Percutaneous Coronary Intervention Procedures","authors":"Akash Kataruka MD ,&nbsp;Kanwar Parhar BS ,&nbsp;David Daniels MD ,&nbsp;Charles Maynard PhD ,&nbsp;Kathleen E. Kearney MD ,&nbsp;Ahmed Mahmoud MD ,&nbsp;Jacob A. Doll MD ,&nbsp;James M. McCabe MD ,&nbsp;William L. Lombardi MD ,&nbsp;Ravi S. Hira MD","doi":"10.1016/j.jscai.2025.104000","DOIUrl":"10.1016/j.jscai.2025.104000","url":null,"abstract":"<div><h3>Background</h3><div>Limited evidence exists for the management of coronary artery perforation. We evaluated temporal trends and clinical outcomes associated with protamine use following coronary artery perforation in patients undergoing percutaneous coronary intervention (PCI) for chronic total occlusions (CTOs).</div></div><div><h3>Methods</h3><div>A single-center retrospective analysis was performed on coronary perforations in patients undergoing CTO PCI procedures between September 10, 2014, and December 31, 2018, encompassing a change in institutional practice regarding use of protamine at case conclusion. The primary outcome was a composite of in-hospital mortality and cardiac tamponade. Multivariate logistic regression analyses were used to assess the association between protamine use and clinical outcomes.</div></div><div><h3>Results</h3><div>In total, 1454 patients undergoing CTO PCI, coronary perforation occurred in 160 (11.0%), of which 68 (42.5%) received protamine. Ellis perforation classification was similar in the protamine and non-protamine groups (<em>P</em> = .148). The primary outcome of in-hospital mortality or cardiac tamponade occurred less frequently in the protamine group compared with the nonprotamine group (11.8% vs 40.2%; <em>P</em> &lt; .01). In-hospital mortality (1.5% vs 14.1%; <em>P</em> = .01) and cardiac tamponade (10.3% vs 26.1%; <em>P</em> = .02) occurred less frequently in the protamine group. In a multivariate logistic regression, protamine was independently associated with an improved primary outcome (OR, 0.27; 95% CI, 0.10-0.65; <em>P</em> &lt; .01).</div></div><div><h3>Conclusions</h3><div>In this retrospective analysis, use of protamine in patients with coronary artery perforation complicating CTO PCI was associated with a reduction in death and cardiac tamponade without evidence of increased stent thrombosis. Additional studies are warranted to establish optimal strategies for protamine use.</div></div>","PeriodicalId":73990,"journal":{"name":"Journal of the Society for Cardiovascular Angiography & Interventions","volume":"4 12","pages":"Article 104000"},"PeriodicalIF":0.0,"publicationDate":"2025-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145754212","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"From Mild Discomfort to Myopericarditis—A Complication of Patent Foramen Ovale Occluder Device Placement: A Case Report","authors":"Anastasia Proshkina MD ,&nbsp;Jonathan Shpigelman MD ,&nbsp;Rami Al Ayyubi MD ,&nbsp;Mohamad Bahrou MD ,&nbsp;Ra’ad Al Tamimi MD ,&nbsp;Ahmad Al Turk MD","doi":"10.1016/j.jscai.2025.104044","DOIUrl":"10.1016/j.jscai.2025.104044","url":null,"abstract":"<div><div>A 43-year-old woman underwent successful elective closure of a large aneurysmal patent foramen ovale (PFO) using a GORE CARDIOFORM Septal Occluder. She experienced mild chest discomfort immediately postprocedure but was discharged after a transthoracic echocardiogram confirmed appropriate device positioning and no acute abnormalities. She returned the following day with worsening pleuritic chest pain unresponsive to acetaminophen and ibuprofen. Her clinical presentation, together with her electrocardiogram, laboratory, and imaging findings, was diagnostic of myopericarditis. She was treated with colchicine and ibuprofen, resulting in complete symptom resolution. This case illustrates a rare complication of PFO closure, potentially related to nickel hypersensitivity. Currently, no validated tools exist to predict such hypersensitivity reactions, and nickel-free PFO closure devices are not commercially available. Until alternatives become available, clinicians must balance the risk of hypersensitivity reactions against the proven benefit of PFO closure in preventing recurrent stroke in select patients.</div></div>","PeriodicalId":73990,"journal":{"name":"Journal of the Society for Cardiovascular Angiography & Interventions","volume":"4 12","pages":"Article 104044"},"PeriodicalIF":0.0,"publicationDate":"2025-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145754218","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Mechanical Circulatory Support for High-Risk Percutaneous Coronary Intervention: Is It a Choice or Chance That Determines Outcomes?","authors":"Ali O. Malik MD, MSc ,&nbsp;Jason R. Wollmuth MD","doi":"10.1016/j.jscai.2025.104021","DOIUrl":"10.1016/j.jscai.2025.104021","url":null,"abstract":"","PeriodicalId":73990,"journal":{"name":"Journal of the Society for Cardiovascular Angiography & Interventions","volume":"4 12","pages":"Article 104021"},"PeriodicalIF":0.0,"publicationDate":"2025-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145754173","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}